Original Investigation  Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial Nicholas A. Turner, Toshimitsu Hamasaki, Sarah B. Doernberg, et al JAMA Published Online: August 13, 2025 doi: 10.1001/jama.2025.12543 Key Points Question  Is dalbavancin a superior treatment option for complicated Staphylococcus aureus bacteremia compared...

Research Letter  Characterization of Research Grant Terminations at the National Institutes of Health Michael Liu, Kushal T. Kadakia, Vishal R. Patel, et al JAMA 2025;334;(6):534-536. doi:10.1001/jama.2025.7707 The National Institutes of Health (NIH) recently initiated a series of grant terminations focused on topics not aligned with agency priorities.1 The scope of terminations, types of grants affected, and differ...

Research Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis Raffaele Piccolo, Angelo Laino, Antonio Pio Vitale, et al BMJ 2025; 390 doi: https://doi.org/10.1136/bmj-2024-082974 (Published 29 July 2025)Cite this as: BMJ 2025;390:e082974 Abstract Objective To evaluate sex related differences in the treatment effect of antithrombotic therapy in patients wit...

Improved SEP-1 Compliance Using AI-Supported Tools In ICU Tue, 20 May 2025 ICU Management & Practice, Volume 25 - Issue 2, 2025 Artificial intelligence (AI) plays an evolving role in optimising sepsis management and SEP-1 compliance. Despite these advances, barriers persist, including alert fatigue, disparities in model performance across diverse settings, and regulatory hurdles in AI deployment. By integrating predictive models with structured...

Original Investigation  Infectious Diseases Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection Mayan Gilboa, Gili Regev-Yochay, Eyal Meltzer, et al JAMA Netw Open Published Online: August 8, 2025 2025;8;(8):e2525252. doi:10.1001/jamanetworkopen.2025.25252 Key Points Question  What is the hazard of Clostridioides difficile infection (CDI) between asymptomatic carriers compared with noncar...

Comment Tackling the burden of β-lactam allergy labels Philip H Li, Kimberly G Blumenthal Lancet Infect Dis 2025; 25: 834-835 Physicians frequently encounter patients who report suspected drug allergies. Many physicians adopt a cautious approach by labelling these unverified drug allergies in their medical records, which often results in patients avoiding the drugs indefinitely. However, it has been recognised that unverified β-lactam allergy labels (BALs), es...

Molecular Subphenotypes in Sepsis and Acute Respiratory Distress Syndrome In ICU Tue, 20 May 2025 ICU Management & Practice, Volume 25 - Issue 2, 2025 Sepsis and Acute Respiratory Distress Syndrome (ARDS) are heterogeneous critical illness syndromes. Molecular subphenotyping shows promise in furthering our understanding of these syndromes and may offer a more precise method for identifying appropriate therapies.  Current Definitions of ...

Articles Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Kidney Failure with Replacement Therapy Collaborators Lancet Global Health 2025; 13: e1378-e1395 Summary Background Kidney failure with replacement therapy (KFRT) such as dialysis or transplantation represents a severe stage of chronic kidney disease...

Articles Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study Miao Cai, Evan Xu, Yan Xie, et al Lancet Infect Dis 2025; 25: 847-860 Summary Background SARS-CoV-2 infection leads to post-acute sequelae that can affect nearly every organ system, including the immune system. However, whether an infection with SARS-CoV-2 is associated wit...

The burden of β-lactam allergy labels in health care: a systematic review and meta-analysis Mengyuan Fu, Lin Hu, Kexin Han, et al Lancet Infect Dis 2025; 25: 896-908 Summary Background Unverified β-lactam allergy labels (BALs) pose a considerable barrier to optimal antimicrobial treatment and represent a growing public health concern. However, no comprehensive meta-analysis has been conducted to explore the associations between BALs and clinical outcomes. W...